Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Cara Therapeutic stock

Learn how to easily invest in Cara Therapeutic stock.

Cara Therapeutic is a biotechnology business based in the US. Cara Therapeutic shares (CARA) are listed on the NASDAQ and all prices are listed in US Dollars. Cara Therapeutic employs 84 staff and has a trailing 12-month revenue of around $48.9 million.

How to buy shares in Cara Therapeutic

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CARA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Cara Therapeutic stock price (NASDAQ: CARA)

Use our graph to track the performance of CARA stocks over time.

Cara Therapeutic shares at a glance

Information last updated 2022-09-27.
Latest market close$9.01
52-week range$7.40 - $18.93
50-day moving average $10.28
200-day moving average $10.58
Wall St. target price$25.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.80

Buy Cara Therapeutic shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cara Therapeutic stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cara Therapeutic price performance over time

Historical closes compared with the close of $9.01 from 2022-09-28

1 week (2022-09-22) 2.39%
1 month (2022-08-30) -13.45%
3 months (2022-06-30) -1.31%
6 months (2022-03-30) -24.92%
1 year (2021-09-30) -41.68%
2 years (2020-09-30) -29.19%
3 years (2019-09-30) 18.28
5 years (2017-09-29) 13.69

Cara Therapeutic financials

Revenue TTM $48.9 million
Gross profit TTM $-59,673,000
Return on assets TTM -18.7%
Return on equity TTM -32.53%
Profit margin -135.72%
Book value $3.81
Market capitalisation $455.6 million

TTM: trailing 12 months

Cara Therapeutic share dividends

We're not expecting Cara Therapeutic to pay a dividend over the next 12 months.

Have Cara Therapeutic's shares ever split?

Cara Therapeutic's shares were split on a 1:2 basis on 15 January 2014. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cara Therapeutic shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for Cara Therapeutic shares which in turn could have impacted Cara Therapeutic's share price.

Cara Therapeutic share price volatility

Over the last 12 months, Cara Therapeutic's shares have ranged in value from as little as $7.4 up to $18.93. A popular way to gauge a stock's volatility is its "beta".

CARA.US volatility(beta: 0.93)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cara Therapeutic's is 0.9349. This would suggest that Cara Therapeutic's shares are less volatile than average (for this exchange).

Cara Therapeutic overview

Cara Therapeutics, Inc. , an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co. , Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea.

Frequently asked questions

What percentage of Cara Therapeutic is owned by insiders or institutions?
Currently 16.176% of Cara Therapeutic shares are held by insiders and 67.095% by institutions.
How many people work for Cara Therapeutic?
Latest data suggests 84 work at Cara Therapeutic.
When does the fiscal year end for Cara Therapeutic?
Cara Therapeutic's fiscal year ends in December.
Where is Cara Therapeutic based?
Cara Therapeutic's address is: 4 Stamford Plaza, Stamford, CT, United States, 06902
What is Cara Therapeutic's ISIN number?
Cara Therapeutic's international securities identification number is: US1407551092
What is Cara Therapeutic's CUSIP number?
Cara Therapeutic's Committee on Uniform Securities Identification Procedures number is: 140755109

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site